Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(11); doi: 10.25236/FMSR.2023.051102.

Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer


Yu Chen1, Hao Cai1, Yang Liu1, Qiao Zhang1, Houjun Jia2

Corresponding Author:
Houjun Jia

1Chongqing Medical University, Chongqing, 400016, China

2Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China


This study aims to assess the correlation between IL-6 concentration in the blood and the efficacy of antiangiogenic therapy for liver metastases from colorectal cancer. In this retrospective study, we examined 53 patients with CRLM who received non-surgical treatment from June 2017 to June 2023. We collected serum IL-6 levels before starting treatment and evaluated their impact based on consensus guidelines. The ROC curve was used to determine the best cut-off point for IL-6. We compared treatment response rates using chi-square tests and estimated overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier and multivariate Cox proportional hazard regression analyses. It was observed that patients who were treated with bevacizumab had a longer progression-free survival (PFS) compared to those who did not receive it (P=0.04). Out of the 24 patients who received chemotherapy alone, 12 had a shorter PFS compared to the remaining 12 who had lower IL-6 levels (P=0.03). Among the 29 patients who were treated with the bevacizumab combination therapy, no significant difference was observed in PFS between the 19 patients who had higher IL-6 levels and the other 10 patients who had lower IL-6 levels (P=0.76). We have concluded that patients with higher levels of IL-6 benefited from antiangiogenic therapy, whereas those with lower levels did not receive the same benefits from bevacizumab.


colorectal cancer, bevacizumab, inflammation, interleukin-6 (IL-6)

Cite This Paper

Yu Chen, Hao Cai, Yang Liu, Qiao Zhang, Houjun Jia. Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer. Frontiers in Medical Science Research (2023) Vol. 5, Issue 11: 10-18. https://doi.org/10.25236/FMSR.2023.051102.


[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492

[2] Ueda S, Saeki T, Osaki A, et al (2017) Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: multimodal functional imaging and multiple cytokine analyses. Angiogenesis 23:5769-5778. https://doi.org/10.1158/1078-0432.ccr-17-0874

[3] Yang Y, Zhang Y, Iwamoto H, et al (2016) Termination of anti-vascular endothelial growth factor (VEGF) cancer therapy promotes metastasis through hepatic revascularization mechanisms. Nature Communications 7:12680. https://doi.org/10.1038/ncomms12680

[4] Lin S-Q, Xie H-L, Ge Y-Z, et al. (2022) Systemic inflammation and water composition in relation to colorectal cancer survival. Frontiers in Oncology 12: https://doi.org/10.3389/fonc.2022.896160

[5] Lin Y, He Z, Ye J, et al (2020) Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer.OncoTargets and Therapy Volume 13:13023-13032. OncoTargets and Therapy Volume 13:13023-13032. https://doi.org/10.2147/ott.s278013

[6] Wang S, Liu Z, Wang L, Zhang X (2009) NF-κB signaling pathway, inflammation and colorectal cancer. Cellular and Molecular Immunology 6:327-334. https://doi.org/10.1038/cmi.2009.43

[7] Saidi A, Hagedorn M, Allain N, et al (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.International Journal of Cancer 125: 1054-1064. https://doi.org/10.1002/ijc.24380

[8] Maniewska J, Jeżewska D (2021) Nonsteroidal anti-inflammatory drugs in colorectal cancer chemoprevention.Cancers 13:594. https://doi.org/10.3390/cancers13040594

[9] Sherwood LM, Parris EE, Folkman J (1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285: 1182-1186. https://doi.org/10.1056/nejm197111182852108

[10] Pavlidis ET (2013) Bevacizumab in colorectal cancer growth and its adverse effects: a review. World Journal of Gastroenterology 19:5051. https://doi.org/10.3748/wjg.v19.i31.5051

[11] Frentzas S, Simoneau E, Bridgeman VL, et al (2016) Vascular coaptation mediates resistance to antitumor therapy in liver metastases. Nature Medicine 22:1294-1302. https://doi.org/10.1038/nm.4197

[12] de Gramont A, Van Cutsem E, Schmoll H-J, et al (2012) Bevacizumab plus Oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomized controlled trial.The Lancet Oncology 13:1225-1233. https://doi.org/10.1016/S1470-2045(12)70509-0

[13] Grivennikov SI (2012) Inflammation and colorectal cancer: colitis-associated tumors. Symposium on Immunopathology 35:229-244. https://doi.org/10.1007/s00281-012-0352-6

[14] Taher MY, Davies DM, Maher J (2018) The role of the interleukin (IL)-6/IL-6 receptor axis in cancer.Biochemical Society Transactions 46:1449-1462. https://doi.org/10.1042/ bst20180136

[15] Hara M, Nagasaki T, Shiga K, et al (2017) Excessive serum interleukin-6 levels in patients with advanced or metastatic colorectal cancer: impact on efficacy and response to chemotherapy plus bevacizumab.Surgery Today 47:483-489. https://doi.org/10.1007/s00595 -016-1404-7

[16] Niu G, Wright KL, Huang M et al (2002) Continuous Stat3 activity upregulates vascular endothelial growth factor expression and tumor angiogenesis.Oncogene 21:2000-2008. https://doi.org/10. 1038/sj. onc. 1205260

[17] Jürgensmeier JM, Schmoll H-J, Robertson JD, et al (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab, and chemotherapy. British Journal of Cancer 108:1316-1323. https://doi.org/10.1038/bjc.2013.79

[18] Wei L-H, Kuo M-L, Chen C-A, et al. (2003) Interleukin-6 promotes cervical tumor growth by promoting vascular endothelial growth factor-dependent angiogenesis through the STAT3 pathway.Oncogene 22:1517-1527. https://doi.org/10.1038/sj. onc.1206226

[19] Mao L, Xin F, Ren J, et al (2022) 5-HT2B-mediated 5-hydroxytryptamine activation in enterocytes inhibits colitis-associated carcinogenesis and promotes cancer progression.Theranostics 12:3928-3945. https://doi.org/10.7150/thno.70762

[20] Nagasaki T, Hara M, Nakanishi H, et al (2013) Interleukin-6 released by colon cancer-associated fibroblasts is essential for tumor angiogenesis: anti-interleukin-6 receptor antibody inhibits angiogenesis and suppresses tumor-stroma interaction. British Journal of Cancer 110:469-478. https: //doi. org/10.1038/bjc.2013.748

[21] Zhang Y, Jin Z, Zhou H, et al (2016) Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Medicine 5:1251–1258. https://doi.org/10.1002/cam4.675

[22] Schwartz LH, Litière S, de Vries E, et al (2016) RECIST 1.1—Update and clarification: From the RECIST committee. European Journal of Cancer 62:132–137. https://doi.org/ 10.1016/j. ejca. 2016. 03.081

[23] Department of Medical Administration of National Health Commission, Oncology Branch of Chinese Medical Association. Chinese standard for diagnosis and treatment of colorectal cancer (2023 edition) [J]. Union Medical Journal, 2023, 14(4): 706-733. doi: 10.12290/xhyxzz.2023-0315